Boehringer Ingelheim receives approval for SENVELGO® in Europe: the fi…

Boehringer Ingelheim, a global leader in animal health, has received marketing authorization from the European Commission for SENVELGO® (active ingredient: velagliflozin), marking a significant step for the treatment of feline diabetes in Europe. Globally, SENVELGO® is the first once-daily liquid oral solution for the reduction of hypoglycemia in cats with non-insulin-dependent diabetes mellitus. This breakthrough innovation will make it easier for cat owners to fit the treatment of feline dia...